

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Age-specific COVID-19 fatality rates, emergency use designation for vaccines, ethics of “safer infection sites”

Peer reviewed journals articles featured:

- Systematic reviews and meta-analyses on:
 - Age specificity of infection fatality rates for COVID-19 [here](#)
 - Male sex as a COVID-19 risk factor for death and ICU admission [here](#)
- A prospective, cross-sectional analysis of SARS-CoV-2 infection and transmission in educational settings [here](#) and associated commentary [here](#)
- Modelling studies on:
 - Strategic spatiotemporal vaccine distribution and survival rate [here](#)
 - Time to $R_t < 1$ for COVID-19 public health lockdown measures [here](#)
- A narrative review on the child public health response to COVID-19 in England [here](#)
- A prospective cohort study on COVID-19 risk by occupational group in the UK [here](#)
- An observational study on side effects of commonly used drugs in the treatment of COVID-19 [here](#)
- Case reports on:
 - COVID-19-associated *Fusobacterium nucleatum* bacteraemia in Belgium [here](#)
 - Evidence of SARS-CoV-2 RNA in an oropharyngeal swab from early December 2019 in Milan, Italy [here](#)
- Commentary on:
 - Granting emergency use designation to COVID-19 candidate vaccines [here](#)
 - The role of genetics and blood type in clinical responses to COVID-19 [here](#)
 - The ethics of SARS-CoV-2 safer infection sites [here](#)
 - Four COVID-19 lessons for achieving health equity [here](#)

Pre-peer review articles featured:

- A rapid living systematic review on long-term COVID-19 [here](#)
- A controlled study on pulmonary rehabilitation in severe and critically ill COVID-19 patients [here](#)

Guidance and reports

- The World Health Organization released guidance on COVID-19 and antimicrobial resistance [here](#)

News and blogs

- Confronting the pathophysiology of long COVID [here](#)
- Pulmonary fungal infections affect patients with COVID-19 [here](#)

Vaccines

- As of 12 December 2020, there are 214 vaccine candidates globally, with 47 vaccine candidates in human clinical trials [here](#)

[Click here](#) to subscribe to the daily evidence digest.

The final digest for 2020 will be released on 18 December and the service will resume on 20 January 2021. A skeleton service will monitor publications over the shutdown period. Should there be any highly significant developments, alerts will be issued to the digest mailing list. Upon resumption of services, key publications released during the break will be collated and a summary distributed.